• ALC-0315 for LNP Formulation and QC

  2026-09-24

  ALC-0315 is an ionizable amino lipid for researchers formulating lipid nanoparticles for mRNA and other nucleic acid drug delivery workflows. It is intended for controlled organic-solvent formulation—not as a water-soluble reagent or a stand-alone delivery system—and its performance must be assessed in the complete LNP formulation.

• Lipo3K Transfection Reagent for ASO Assays

  2026-09-24

  Pair a low-toxicity lipid delivery workflow with careful testing of nucleic-acid designs, from plasmid reporters to siRNA controls. The article’s pH-responsive ASO findings suggest practical assay questions—but do not establish Lipo3K as a validated delivery method for those ASOs.

• Nonivamide: TRPV1 Workflows for Cancer Research

  2026-09-23

  Use Nonivamide as a TRPV1 probe for acute calcium signaling and as a candidate for dose- and time-resolved cancer cell assays. A dermatitis study offers a useful sensory-neuron assay framework, but its capsaicin findings should not be mistaken for direct testing of Nonivamide.

• From mRNA Capping to Bladder Cancer Translation

  2026-09-23

  A translational analysis of p21 mRNA–loaded lipid nanoparticles for bladder cancer, showing how localized delivery, tumor suppressor biology, and disciplined mRNA manufacturing can converge. The article also positions EZ Cap™ Reagent GG as an upstream reagent to evaluate within a controlled IVT and LNP development workflow.

• Palonosetron for CINV and RINV: 2013 Review

  2026-09-22

  This review synthesized pharmacology, clinical trials, guideline positioning, and emerging combination strategies for palonosetron hydrochloride in radio- and chemotherapy-induced nausea and vomiting. Its main contribution was to connect high-affinity, long-lasting 5-HT3 receptor antagonism with improved control of delayed symptoms after moderately emetogenic chemotherapy, while identifying evidence gaps in multiple-day treatment and broader combination regimens.

• seRNA-NPCm Drives Nasopharyngeal Carcinoma Metastasis

  2026-09-22

  The 2023 study identifies a carcinogen-responsive super-enhancer RNA, seRNA-NPCm, as a regulator of nasopharyngeal carcinoma metastasis. Integrated transcriptomic, nascent-transcription, chromatin, functional, and patient-tissue analyses connect seRNA-NPCm with an NPM1/c-Myc/NDRG1 regulatory axis and provide a mechanistic framework for studying carcinogen-associated enhancer dysregulation.

• Zebrafish CCK-8 and Anxiety-Like Behavior

  2026-09-21

  The reference study mapped CCK-like immunoreactivity in the zebrafish brain and tested two sulfated CCK octapeptide forms using intracerebroventricular administration. Both peptides produced dose-dependent anxiety-like behavior at the highest tested dose, while proglumide attenuated the response, supporting CCK receptor signaling as a conserved neurobehavioral pathway.

• Digoxin Workflows for Ion-Pump and CHIKV Research

  2026-09-21

  Digoxin provides a mechanistically defined way to study Na+/K+ ATPase signaling, cardiac contractility modulation, and cell-context-dependent inhibition of chikungunya virus infection. This workflow-focused guide covers dose design, solvent control, translational model selection, and troubleshooting for cardiovascular and antiviral experiments.

• ALC-0315: Practical LNP Formulation Guide

  2026-09-20

  ALC-0315 is an ionizable amino lipid for developing lipid nanoparticles used in nucleic acid drug delivery, including mRNA vaccine research. It is intended for controlled organic-solvent formulation workflows, not as a water-soluble standalone reagent or evidence of a validated clinical formulation.

• Calpain Inhibitor I, ALLN: Protocol Guide

  2026-09-19

  Calpain Inhibitor I, ALLN (SKU A2602) provides a research tool for probing calpain- and cathepsin-dependent proteolysis in apoptosis, inflammation research, and ischemia-reperfusion injury workflows. It should be treated as a pathway perturbation reagent rather than a calpain-exclusive probe, and it is not intended for diagnostic, clinical, or water-based applications.

• Stat3 in Fyn-Driven Dopaminergic Neurodegeneration

  2026-09-18

  A 2024 Disease Models & Mechanisms study developed a neural-specific zebrafish model of constitutively active Fyn kinase and linked dopaminergic neuron loss to microglial inflammation. Live imaging, transcriptomics, and pathway inhibition identify Stat3 as a downstream Fyn effector that cooperates with NF-κB, providing a mechanistic framework for studying kinase-associated neurodegeneration.

• Crystal Violet Staining Solution: Assay Workflow

  2026-09-18

  Turn fixed cells, colonies, and transwell endpoints into high-contrast, imageable data with a practical nuclear staining dye workflow. This guide distinguishes nuclear visualization from total biomass measurement and provides optimization steps for proliferation, migration, invasion, and colony assays.

• Worenine and PBK/SRC Signaling in Pulmonary Fibrosis

  2026-09-17

  This study integrates network pharmacology, molecular docking, and cellular and animal validation to examine how worenine may alleviate pulmonary fibrosis. Its central contribution is linking worenine activity to PBK/SRC-associated regulation of TGF-β1/Smad, ERK, and NF-κB signaling, while identifying effects on epithelial–mesenchymal transition, fibroblast–myofibroblast transition, collagen deposition, and inflammatory mediator release.

• D-Luciferin sodium salt for CAR-M Imaging

  2026-09-17

  D-Luciferin sodium salt converts firefly luciferase expression, cellular ATP availability, and viable cell burden into a practical optical readout for CAR-macrophage studies. This workflow helps distinguish longitudinal tumor tracking from functional metabolism measurements in mRNA-LNP immunotherapy experiments.

• IMP (M1405) for Reliable Cell Assays

  2026-09-16

  This scenario-based guide explains how to evaluate IMP (SKU M1405) for cell viability, proliferation, and cytotoxicity workflows without overstating undocumented performance. It focuses on assay compatibility, controls, quantitative readouts, cross-assay interpretation, and practical vendor-selection criteria.

8340 records 1/556 page Next 12345 下5页 Last page